Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston.
Department of Thoracic Cancer, Hubei Cancer Hospital, Wuhan, China.
JAMA Oncol. 2019 Jun 1;5(6):841-846. doi: 10.1001/jamaoncol.2019.0062.
The recent parenteral opioid shortage (POS) has potential implications for cancer-related pain management in hospitalized patients.
This study compared changes in opioid prescriptions and clinically improved pain (CIP) among patients treated by an inpatient palliative care (PC) team before and after our institution first reported the POS.
DESIGN, SETTING, AND PARTICIPANTS: A cohort study of 386 eligible patients with cancer treated at a comprehensive cancer center 1 month before and after the announcement of the POS. We reviewed data from electronic health records, including patient demographics, opioid type, route of administration, and dose. Board-certified palliative care specialists assessed CIP at follow-up day 1.
The announcement of the POS by the institution's pharmacy and therapeutics committee on February 8, 2018.
The primary outcome was to measure the change in opioid prescription patterns of physicians, and the secondary outcome was to measure the proportion of patients who achieved CIP before and after announcement of the POS.
Of 386 eligible patients, 196 were men (51%), 270 were white (70%), and the median age was 58 years (interquartile range, 46-67 years). Parenteral opioids were prescribed less frequently by the referring oncology teams after the POS (56 of 314 [18%]) vs before the POS (109 of 311 [35%]) (P < .001). The PC team also prescribed fewer parenteral opioids after the POS (96 of 336 [29%]) vs before the POS (159 of 338 [47%]) (P < .001). After the POS (vs before the POS), significantly fewer patients achieved CIP on follow-up day 1 (119 [62%] vs 144 [75%] of 193; P = .01). Multivariate analysis showed that before the POS, patients had an 89% higher chance of achieving CIP on follow-up day 1 (odds ratio, 1.89; 95% CI, 1.22-2.94; P = .005).
There was a significant change in opioid prescription patterns associated with the POS. Furthermore, after the POS, fewer patients achieved CIP. These factors have potential implications for patient satisfaction and hospital length of stay.
最近的肠外阿片类药物短缺(POS)可能对住院患者的癌症相关疼痛管理产生影响。
本研究比较了在我们机构首次报告 POS 前后,接受住院姑息治疗(PC)团队治疗的患者的阿片类药物处方和临床改善疼痛(CIP)的变化。
设计、地点和参与者:这是一项在综合癌症中心进行的队列研究,共纳入了 386 名符合条件的癌症患者,他们在 POS 宣布前和宣布后各有 1 个月的时间。我们从电子健康记录中回顾了患者的人口统计学数据、阿片类药物类型、给药途径和剂量。经董事会认证的姑息治疗专家在随访第 1 天评估 CIP。
机构药房和治疗委员会于 2018 年 2 月 8 日宣布 POS。
主要结果是测量医生开阿片类药物处方模式的变化,次要结果是测量 POS 宣布前后达到 CIP 的患者比例。
在 386 名符合条件的患者中,196 名男性(51%),270 名白人(70%),中位年龄为 58 岁(四分位距,46-67 岁)。POS 后,肿瘤学团队开具的肠外阿片类药物处方频率降低(POS 后 314 例中有 56 例[18%],POS 前 311 例中有 109 例[35%])(P <.001)。PC 团队开具的肠外阿片类药物处方也减少了(POS 后 336 例中有 96 例[29%],POS 前 338 例中有 159 例[47%])(P <.001)。POS 后,在随访第 1 天达到 CIP 的患者明显减少(POS 后 193 例中有 119 例[62%],POS 前 193 例中有 144 例[75%])(P =.01)。多变量分析显示,POS 前,患者在随访第 1 天达到 CIP 的可能性高出 89%(优势比,1.89;95%CI,1.22-2.94;P =.005)。
POS 后阿片类药物处方模式发生了显著变化。此外,POS 后达到 CIP 的患者更少。这些因素可能对患者满意度和住院时间产生影响。